• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

止血变量在血栓形成和出血中的生物学变异:对性能规格的影响。

Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications.

机构信息

Department of Haematology, Erasmus Medical Center, Rotterdam;

Department of Haematology, Erasmus Medical Center, Rotterdam.

出版信息

Clin Chem. 2016 Dec;62(12):1639-1646. doi: 10.1373/clinchem.2016.261248. Epub 2016 Sep 27.

DOI:10.1373/clinchem.2016.261248
PMID:27679435
Abstract

BACKGROUND

Levels of hemostasis factors vary between and within individuals as a result of genetic and environmental factors and analytical variation of the assays. The current state of the art for defining analytical precision requirements for analytical testing is based on this between- and within-individual (biological) variation. However, information on biological variation in hemostasis variables is still limited.The aim of this study was to determine the biological variation of coagulation variables involved in thrombosis and bleeding to provide a recommendation for performance specifications and to assess whether hemostasis assays fulfill the recommendation.

METHODS

We performed a longitudinal study by repeated blood sampling (in total 13 times over a 1-year period) in 40 healthy individuals and measured prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, antithrombin, factor VIII, factor IX, von Willebrand factor (VWF), protein C, and protein S. We evaluated the effect of the biological variation on parameters of analytical variation and propose required performance specifications.

RESULTS

Biological variation was highly different for various hemostasis variables: the within-subject variation ranged from 2.6% (PT) to 25.6% [VWF collagen binding (CB) activity], the between-subject variation varied from 4.1% (PT) to 31.2% (VWF:ristocetin cofactor acitivity), and the assay variation from 1.3% (PT) to 12.9% (VWF:CB).

CONCLUSIONS

With the reagents and analyzers used in this study, most of the hemostasis tests variables fulfill the current quality criteria for diagnosis and monitoring of routine hemostasis assays.

摘要

背景

由于遗传和环境因素以及分析检测的变化,止血因子的水平在个体之间和个体内部存在差异。目前,定义分析测试分析精度要求的最新技术是基于这种个体内和个体间(生物学)的变化。然而,关于止血变量生物学变异的信息仍然有限。本研究的目的是确定参与血栓形成和出血的凝血变量的生物学变异,为性能规范提供建议,并评估止血检测是否符合建议。

方法

我们通过对 40 名健康个体进行重复采血(在 1 年内共采血 13 次)进行了一项纵向研究,并测量了凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原、抗凝血酶、VIII 因子、IX 因子、血管性血友病因子(VWF)、蛋白 C 和蛋白 S。我们评估了生物学变异对分析变异参数的影响,并提出了所需的性能规范。

结果

各种止血变量的生物学变异差异很大:个体内变异范围为 2.6%(PT)至 25.6%[VWF 胶原结合(CB)活性],个体间变异范围为 4.1%(PT)至 31.2%(VWF:瑞斯托霉素辅因子活性),检测变异范围为 1.3%(PT)至 12.9%(VWF:CB)。

结论

使用本研究中的试剂和分析仪,大多数止血测试变量都符合当前用于诊断和监测常规止血检测的质量标准。

相似文献

1
Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications.止血变量在血栓形成和出血中的生物学变异:对性能规格的影响。
Clin Chem. 2016 Dec;62(12):1639-1646. doi: 10.1373/clinchem.2016.261248. Epub 2016 Sep 27.
2
Coagulation Testing in the Core Laboratory.核心实验室中的凝血检测
Lab Med. 2017 Nov 8;48(4):295-313. doi: 10.1093/labmed/lmx050.
3
Evaluation and performance characteristics of the Q Hemostasis Analyzer, an automated coagulation analyzer.Q凝血分析仪(一种自动凝血分析仪)的评估及性能特点
Thromb Res. 2014 May;133(5):927-35. doi: 10.1016/j.thromres.2014.02.021. Epub 2014 Feb 28.
4
Within-subject biological variation of activated partial thromboplastin time, prothrombin time, fibrinogen, factor VIII and von Willebrand factor in pregnant women.孕妇活化部分凝血活酶时间、凝血酶原时间、纤维蛋白原、VIII 因子和血管性血友病因子的个体内生物学变异。
Clin Chem Lab Med. 2018 Jul 26;56(8):1297-1308. doi: 10.1515/cclm-2017-1220.
5
Evaluation of primary haemostasis in people with neurofibromatosis type 1.1型神经纤维瘤病患者原发性止血功能的评估。
Clin Lab Haematol. 2004 Oct;26(5):341-5. doi: 10.1111/j.1365-2257.2004.00632.x.
6
Lifestyle Intervention Improves Prothrombotic Coagulation Profile in Individuals at High Risk for Type 2 Diabetes.生活方式干预可改善 2 型糖尿病高危人群的血栓前凝血谱。
J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3198-e3207. doi: 10.1210/clinem/dgab124.
7
Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.口服避孕药对在使用口服避孕药期间发生深静脉血栓形成的女性的止血作用。
Thromb Haemost. 1998 Sep;80(3):382-7.
8
Prothrombotic State Induced by Middle-Distance Endurance Exercise in Middle-Aged Athletes.中年运动员中长跑诱发的血栓前状态。
Semin Thromb Hemost. 2018 Nov;44(8):747-755. doi: 10.1055/s-0038-1667115. Epub 2018 Aug 17.
9
Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism.左甲状腺素治疗对甲状腺功能减退症患者生化及止血参数的影响。
Eur J Endocrinol. 2005 Mar;152(3):355-61. doi: 10.1530/eje.1.01857.
10
Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis.慢性非肝硬化性门静脉血栓形成患者的高凝状态。
Clin Gastroenterol Hepatol. 2012 Jan;10(1):72-8. doi: 10.1016/j.cgh.2011.09.010. Epub 2011 Sep 23.

引用本文的文献

1
Time to integrate measurement uncertainty in method comparison and interpretation of hemostasis laboratory assays.是时候将测量不确定度纳入止血实验室检测的方法比较和结果解读中了。
Res Pract Thromb Haemost. 2025 Aug 5;9(6):102993. doi: 10.1016/j.rpth.2025.102993. eCollection 2025 Aug.
2
Intraindividual variability of von Willebrand factor and the need for repeated testing.血管性血友病因子的个体内变异性及重复检测的必要性。
Res Pract Thromb Haemost. 2025 May 17;9(4):102889. doi: 10.1016/j.rpth.2025.102889. eCollection 2025 May.
3
Levels of Fibrinogen Variants Are Altered in Severe COVID-19.
严重新型冠状病毒肺炎患者中纤维蛋白原变体水平发生改变。
TH Open. 2023 Jul 13;7(3):e217-e225. doi: 10.1055/a-2102-4521. eCollection 2023 Jul.
4
Altered fibrin network structure and fibrinolysis in intensive care unit patients with COVID-19, not entirely explaining the increased risk of thrombosis.新冠肺炎重症监护病房患者纤维蛋白网络结构改变和纤溶异常,并不能完全解释其血栓形成风险增加。
J Thromb Haemost. 2022 Jun;20(6):1412-1420. doi: 10.1111/jth.15708. Epub 2022 Apr 1.
5
ADAMTS-13 and bleeding phenotype in von Willebrand disease.血管性血友病中的ADAMTS-13与出血表型
Res Pract Thromb Haemost. 2020 Oct 31;4(8):1331-1339. doi: 10.1002/rth2.12442. eCollection 2020 Nov.
6
Coagulation Changes during Central Hypovolemia across Seasons.不同季节中心性低血容量时的凝血变化
J Clin Med. 2020 Oct 27;9(11):3461. doi: 10.3390/jcm9113461.
7
Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests.评估DOAC-Stop®程序以克服直接口服抗凝剂(DOACs)对多项血栓形成倾向筛查试验的影响。
TH Open. 2018 Jun 1;2(2):e202-e209. doi: 10.1055/s-0038-1657785. eCollection 2018 Apr.
8
Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease.与较高 von Willebrand 因子 (VWF) 水平相关的合并症可能解释了 von Willebrand 病中 VWF 随年龄增长而增加的原因。
Br J Haematol. 2018 Jul;182(1):93-105. doi: 10.1111/bjh.15277. Epub 2018 May 16.
9
Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype.在一项多中心3期临床试验中通过血栓弹力图评估重组因子VIII Fc(Eloctate)活性及其与出血表型的相关性。
Blood Coagul Fibrinolysis. 2017 Oct;28(7):540-550. doi: 10.1097/MBC.0000000000000638.